Cargando…
The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma
Programs to eliminate trachoma as a public health problem use prevalence of the clinical sign trachomatous inflammation—follicular (TF) in 1- to 9-year-olds in endemic districts to make decisions to begin or end mass drug administration with azithromycin. Trachomatous inflammation—follicular is used...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Tropical Medicine and Hygiene
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592184/ https://www.ncbi.nlm.nih.gov/pubmed/34398819 http://dx.doi.org/10.4269/ajtmh.21-0541 |
_version_ | 1784599408894017536 |
---|---|
author | Gwyn, Sarah Nute, Andrew W. Sata, Eshetu Tadesse, Zerihun Chernet, Ambahun Haile, Mahteme Zeru, Taye Bethea, Danaya Laurent, Christian Callahan, E. Kelly Nash, Scott D. Martin, Diana L. |
author_facet | Gwyn, Sarah Nute, Andrew W. Sata, Eshetu Tadesse, Zerihun Chernet, Ambahun Haile, Mahteme Zeru, Taye Bethea, Danaya Laurent, Christian Callahan, E. Kelly Nash, Scott D. Martin, Diana L. |
author_sort | Gwyn, Sarah |
collection | PubMed |
description | Programs to eliminate trachoma as a public health problem use prevalence of the clinical sign trachomatous inflammation—follicular (TF) in 1- to 9-year-olds in endemic districts to make decisions to begin or end mass drug administration with azithromycin. Trachomatous inflammation—follicular is used as a proxy for transmission of ocular Chlamydia trachomatis infection. Long-term monitoring of previously endemic districts for recrudescence of ocular C. trachomatis infection would benefit from a simple blood test that could be integrated with other public health programs. In this study, we evaluated multiple tests to measure antibodies against the C. trachomatis antigen Pgp3—a multiplex bead assay (MBA), an ELISA, and two versions of a lateral flow assay (LFA)—in four districts of the Amhara region of Ethiopia with varying levels of TF. Seroprevalence and seroconversion rate (SCR) results were proportional to TF prevalence by district for most tests, with the notable exception of the LFA using colloidal gold as the developing reagent. Changing the test developing reagent to black latex improved agreement between serological measures and TF prevalence and in inter-rater agreement. Seroconversion rate estimates using data derived from the LFA-gold assay were inconsistent with the shape of the age-seroprevalence curve, which did not increase in older ages. These data revealed potential complications with using SCR that will need further evaluation. Data from MBA, ELISA, and LFA with the black test line showed good agreement with each other and proportionality to TF estimates, providing further data that serology has potential utility for trachoma surveillance. |
format | Online Article Text |
id | pubmed-8592184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The American Society of Tropical Medicine and Hygiene |
record_format | MEDLINE/PubMed |
spelling | pubmed-85921842021-11-24 The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma Gwyn, Sarah Nute, Andrew W. Sata, Eshetu Tadesse, Zerihun Chernet, Ambahun Haile, Mahteme Zeru, Taye Bethea, Danaya Laurent, Christian Callahan, E. Kelly Nash, Scott D. Martin, Diana L. Am J Trop Med Hyg Article Programs to eliminate trachoma as a public health problem use prevalence of the clinical sign trachomatous inflammation—follicular (TF) in 1- to 9-year-olds in endemic districts to make decisions to begin or end mass drug administration with azithromycin. Trachomatous inflammation—follicular is used as a proxy for transmission of ocular Chlamydia trachomatis infection. Long-term monitoring of previously endemic districts for recrudescence of ocular C. trachomatis infection would benefit from a simple blood test that could be integrated with other public health programs. In this study, we evaluated multiple tests to measure antibodies against the C. trachomatis antigen Pgp3—a multiplex bead assay (MBA), an ELISA, and two versions of a lateral flow assay (LFA)—in four districts of the Amhara region of Ethiopia with varying levels of TF. Seroprevalence and seroconversion rate (SCR) results were proportional to TF prevalence by district for most tests, with the notable exception of the LFA using colloidal gold as the developing reagent. Changing the test developing reagent to black latex improved agreement between serological measures and TF prevalence and in inter-rater agreement. Seroconversion rate estimates using data derived from the LFA-gold assay were inconsistent with the shape of the age-seroprevalence curve, which did not increase in older ages. These data revealed potential complications with using SCR that will need further evaluation. Data from MBA, ELISA, and LFA with the black test line showed good agreement with each other and proportionality to TF estimates, providing further data that serology has potential utility for trachoma surveillance. The American Society of Tropical Medicine and Hygiene 2021-11 2021-08-16 /pmc/articles/PMC8592184/ /pubmed/34398819 http://dx.doi.org/10.4269/ajtmh.21-0541 Text en © The American Society of Tropical Medicine and Hygiene https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Article Gwyn, Sarah Nute, Andrew W. Sata, Eshetu Tadesse, Zerihun Chernet, Ambahun Haile, Mahteme Zeru, Taye Bethea, Danaya Laurent, Christian Callahan, E. Kelly Nash, Scott D. Martin, Diana L. The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma |
title | The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma |
title_full | The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma |
title_fullStr | The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma |
title_full_unstemmed | The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma |
title_short | The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma |
title_sort | performance of immunoassays to measure antibodies to the chlamydia trachomatis antigen pgp3 in different epidemiological settings for trachoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592184/ https://www.ncbi.nlm.nih.gov/pubmed/34398819 http://dx.doi.org/10.4269/ajtmh.21-0541 |
work_keys_str_mv | AT gwynsarah theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT nuteandreww theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT sataeshetu theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT tadessezerihun theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT chernetambahun theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT hailemahteme theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT zerutaye theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT betheadanaya theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT laurentchristian theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT callahanekelly theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT nashscottd theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT martindianal theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT gwynsarah performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT nuteandreww performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT sataeshetu performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT tadessezerihun performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT chernetambahun performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT hailemahteme performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT zerutaye performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT betheadanaya performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT laurentchristian performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT callahanekelly performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT nashscottd performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma AT martindianal performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma |